Discontinuation of antidepressants in remitted anxiety disorder patients: The need for strategies to prevent relapse

Psychotherapy and Psychosomatics

Volumn 82, Issue 6, 2013, Pages 399-400

  Scholten, Willemijn D ^a,b   Batelaan, Neeltje M ^a,b   Van Oppen, Patricia ^a,b   Smit, Johannes H ^a   Van Balkom, Anton J L M ^a,b  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; BENZODIAZEPINE DERIVATIVE;

ANXIETY DISORDER; COGNITIVE THERAPY; DEPRESSION; DRUG WITHDRAWAL; HUMAN; LETTER; LONG TERM CARE; MAINTENANCE THERAPY; PREVENTION STUDY; PRIORITY JOURNAL; RELAPSE; REMISSION;

ANTIDEPRESSIVE AGENTS; ANXIETY DISORDERS; COGNITIVE THERAPY; EVIDENCE-BASED MEDICINE; HUMANS; MEDICATION ADHERENCE; RECURRENCE;

EID: 84886260836     PISSN: 00333190     EISSN: 14230348     Source Type: Journal    
DOI: 10.1159/000350450     Document Type: Letter

References (10)

1. Walker JR, Van Ameringen MA, Swinson R, Bowen RC, Chokka PR, Goldner E, Johnston DC, Lavallie YJ, Nandy S, Pecknold JC, Hadrava V, Lane RM: Prevention of relapse in generalized social phobia: results of a 24-week study in responders to 20 weeks of sertraline treatment. J Clin Psychopharmacol 2000; 20: 636-644.
2. Lotufo-Neto F, Bernik M, Ramos RT, Andrade L, Gorenstein C, Cordas T, Melo M, Gentil V: A dose-finding and discontinuation study of clomipramine in panic disorder. J Psychopharmacol 2001; 15: 13-17.
3. Rickels K, Etemad B, Khalid-Khan S, Lohoff FW, Rynn MA, Gallop RJ: Time to relapse after 6 and 12 months' treatment of generalized anxiety disorder with venlafaxine extended release. Arch Gen Psychiatry 2010; 67: 1274-1281.
4. Belaise C, Gatti A, Chouinard VA, Chouinard G: Patient online report of selective serotonin reuptake inhibitor-induced persistent postwithdrawal anxiety and mood disorders. Psychother Psychosom 2012; 81: 386-388.
5. Fava GA, Bernardi M, Tomba E, Rafanelli C: Effects of gradual discontinuation of selective serotonin reuptake inhibitors in panic disorder with agoraphobia. Int J Neuropsychopharmacol 2007; 10: 835-838.
6. Fava GA, Offidani E: The mechanisms of tolerance in antidepressant action. Prog Neuropsychopharmacol Biol Psychiatry 2011; 35: 1593-1602.
7. Baldessarini RJ, Tondo L, Ghiani C, Lepri B: Illness risk following rapid versus gradual discontinuation of antidepressants. Am J Psychiatry 2010; 167: 934-941.
8. Vittengl JR, Clark LA, Dunn TW, Jarrett RB: Reducing relapse and recurrence in unipolar depression: A comparative meta-analysis of cognitivebehavioral therapy's effects. J Consult Clin Psychol 2007; 75: 475-488.
9. Fava GA, Rafanelli C, Grandi S, Conti S, Ruini C, Mangelli L, Belluardo P: Long-term outcome of panic disorder with agoraphobia treated by exposure. Psychol Med 2001; 31: 891-898.
10. Hiss H, Foa EB, Kozak MJ: Relapse prevention program for treatment of obsessive-compulsive disorder. J Consult Clin Psychol 1994; 62: 801-808.